According to a study, the demand for cardiovascular drugs in India will grow at about 13.5 per cent, per annum till 2011, the highest growth rate among all therapeutic groups.
"With this launch, we will make the entry into India and pave the way for many more research products to be introduced in the future," said V Vijayendran, president, Daiichi Sankyo India Pharma.
The $8-billion Daiichi Sankyo, Japan's second largest pharma company, recently set up its subsidiary in India to tap the potential of the Rs 35,000-crore domestic retail drug market.
With a turnover of over Rs 1,700 crore, GlaxoSmithKline Pharmaceuticals is one of the top pharmaceutical companies in India. The company employs more than 3,500 people.
